All Oncology News

Treatment with encorafenib and binimetinib improved survival versus single-agent vemurafenib (Zelboraf) in patients with BRAF-mutant advanced, unresectable or metastatic melanoma.

Enrico Tiacci, MD, discusses the high potential with the combination of vemurafenib and rituximab in relapsed/refractory patients with hairy cell leukemia.

The combination of nivolumab and ipilimumab improved progression-free survival compared with chemotherapy in treatment-naïve patients with high tumor mutation burden non–small cell lung cancer.

Arjun V. Balar, MD, discusses the landscape of current and future standards of care for immunotherapy in bladder and kidney cancer.

Prexasertib (LY2606368) induced a 29% response rate with acceptable tolerability in women with measurable, recurrent high-grade serous or high-grade endometrioid ovarian carcinoma.

A statistical model that combines multiple variables such as tumor size and lymph-node status into a single score can improve patient selection for breast cancer clinical trials and produce stronger results.

The neoadjuvant combination of palbociclib (Ibrance), pertuzumab (Perjeta), fulvestrant (Faslodex), and trastuzumab (Herceptin), cut expression of Ki67 and induced an overall clinical response of 29% in women with ER-positive/HER2-positive breast cancer.

Adding docetaxel to androgen-deprivation therapy improved overall survival by nearly 17 months in men with high-volume metastatic hormone-sensitive prostate cancer.

One out of 6 survivors of childhood cancer was unemployed, according to results from a meta-analysis of 56 studies conducted in the United States, Canada, Asia, and Europe.

Patients with advanced renal cell carcinoma treated with cabozantinib had similar quality of life outcomes as those treated with everolimus.

At a median follow-up of 13.1 months, tisagenlecleucel (Kymriah) induced an overall remission rate of 81% in children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia.

Samir Taneja, MD, discusses his research on MRI-guided prostate biopsies and other modalities in development.

Frederick L. Locke, MD, discusses the initial data for axicabtagene ciloleucel (axi-cel; Yescarta) plus atezolizumab (Tecentriq) in diffuse large B-cell lymphoma, and reflected on the long-term survival data from the ZUMA-1 trial.

Jean-Bernard Durand, MD, discusses implantable cardiac devices and how patients may be able to continue their treatment regimen.

Rashmi K. Murthy, MD, MBE, discusses the role of tucatinib in CNS metastases for patients with HER2-positive breast cancer.

Sharad Ghamande, MD, discusses the findings from GOG/NRG-0265, as well as the impact of vaccines for patients with cervical cancer.

Akihito Kawazoe, MD, discusses the study of napabucasin plus pembrolizumab in mCRC.

Arun S. Singh, MD, discusses the developing role of immunotherapy in patients with GISTs, particularly the randomized phase II trial investigating nivolumab as a single agent and in combination with ipilimumab.

The FDA has halted 4 US studies of BPX-501, a novel cellular immunotherapy for cancers and orphan inherited blood disorders, after 3 patients developed encephalopathy possibly related to treatment with BPX-501.

Daniel Coit, MD, discusses clinical findings with complete lymph node dissection and the evolution of surgery in the melanoma landscape.

The trastuzumab (Herceptin) biosimilar SB3 induced a rate of breast pathologic complete response similar to trastuzumab in women with HER2-positive breast cancer, according to results from a phase III study of 800 patients.

The European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion recommending a label variation for carfilzomib in patients with relapsed/refractory multiple myeloma.

Enzalutamide showed promising clinical activity in patients with androgen receptor–positive triple-negative breast cancer.

David R. Wise, MD, PhD, discusses the promise for immunotherapy and other emerging approaches in the field of prostate cancer.

The annual update on oncology treatment highlights the most impactful clinical cancer research and policy developments over the past year in CAR T-cell therapy.

Marc A. Bjurlin, DO, discusses ongoing efforts to optimize prostate cancer screening.

David G. Maloney, MD, PhD, discusses the promise of lisocabtagene maraleucel in patients with diffuse large B-cell lymphoma.

Jesus Berdeja, MD, discusses ongoing research with bb2121 in patients with relapsed/refractory myeloma.

Michael J. Pishvaian, MD, PhD, discusses the findings with entrectinib in this population, as well as the potential implications of widespread molecular testing in pancreatic cancer.

Mario Sznol, MD, discusses overall advances in the field of melanoma, as well as novel treatments with the potential to change the treatment paradigm.